Press Releases

Funds will enable the completion of the ongoing Phase 2a clinical trial growing ectopic livers for patients with end stage liver disease and advance LyGenesis's pipeline of cell therapies  ...

Merger to result in NYSE American-listed company focused on developing therapeutics based on Serina’s proprietary POZ Platform™ delivery technology Lead program of the combined company will be SER-252 (POZ-apomorphine) for the...

PITTSBURGH, April 11, 2023 /PRNewswire/ -- LyGenesis, Inc., a clinical-stage biotechnology company developing allogenic cell therapies for large unmet needs, and Imagine Pharma, a biotechnology company focused on the development of its novel polypeptide (IMG-1)...

LONDON--(BUSINESS WIRE)--Relation Therapeutics, a leader in the use of high-resolution biology, machine learning and clinical insights to discover life-changing medicines, announced today the opening of their flagship integrated wet–dry laboratory....

February 15, 2023 - Boston, MA – Morphoceuticals Inc., a biotechnology company, announced it closed an $8 million Seed-2 funding round led by Prime Movers Lab and initial investor Juvenescence....

Juvenescence has named Dr Richard Marshall CBE as its new CEO, effective 16 January 2023. Dr Marshall succeeds co-founder Dr Gregory Bailey, who will remain on the company’s board as...

Biotech Leader to Provide Longevity Insights at Annual Conference  Ramsey, Isle of Man – November 1, 2022 – Juvenescence Limited (“Juvenescence”), a life sciences company developing therapies and consumer products...

AgeX Therapeutics announces a manufacturing, marketing and distribution agreement with Pluristyx, an advanced therapy tools and services company, to expand access to clinical-grade human pluripotent stem cells for therapeutic applications.

LyGenesis announces four new peer-reviewed publications highlighting its advancing technology for kidney and liver regeneration.

iTolerance and LyGenesis announced a collaboration to evaluate the potential of iTOL-201 combined with LyGenesis' liver cell therapy (LYG-LIV-100), to enable ectopic livers to be grown without the need or immune...

Juvenescence joins the 200M Fund portfolio in the investment in Chrysea Labs (“Chrysea”), a synthetic biology company developing high-value and difficult to source natural products, using proprietary synthetic biology platforms.

Relation Therapeutics announced today it had raised a $25 million investment and hired a Chief Executive Officer and Chief Technology Officer, enabling Relation to advance therapeutic candidates for diseases with...